Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle, F Peyraud, L Belcaid, M Brunet, M Aldea, R Clodion, P Dubos, D Vasseur, C Nicotra, A Geraud, M Sakkal, L Cerbone, F Blanc-Durand, F Mosele, P Martin Romano, M Ngo Camus, I Soubeyran, E Khalifa, M Alame, L BlouinD Dinart, C Bellera, A Hollebecque, S Ponce, Y Loriot, B Besse, L Lacroix, E Rouleau, F Barlesi, F Andre, A Italiano*

*Corresponding author af dette arbejde
TidsskriftAnnals of Oncology
Udgave nummer12
Sider (fra-til)1328-1331
Antal sider4
StatusUdgivet - dec. 2022